Interstitial lung disease (ILD) is a relevant extra‐articular manifestation of rheumatoid
arthritis (RA) that may occur either in early stages or as a complication of long‐standing …

Objective Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized
controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in …

The lungs are frequently involved in Connective Tissue Diseases (CTDs). Interstitial lung
disease (ILD) is one of the most common pleuropulmonary manifestations that affects …

Objectives. The prevalence of interstitial lung disease (ILD) in RA is∼ 5%. Previous work
identified increasing age, active articular disease and articular damage as risk factors for RA …

Background Uncertainty exists regarding the clinical relevance of exercise training across
the range of interstitial lung diseases (ILDs). Objective To establish the impact of exercise …

Objective This study explores whether the prognosis of interstitial lung disease in
rheumatoid arthritis (RA-ILD) has improved over time and assesses the potential influence of …

Introduction Acute exacerbation (AE) is a devastating phenomenon and reported to be
complicated with systemic autoimmune disease-associated interstitial lung disease (ILD) …

Rheumatoid arthritis (RA) is considered a systemic inflammatory disease marked by
polyarthritis which affects the joints symmetrically, leading to progressive damage of the …

Multiple cells play critical roles in the pathogenesis of lung diseases, even though the exact
mechanisms are still not clear. Telocytes are characterized by telopodes, which are thin and …

Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with
systemic sclerosis (SSc). Although a large proportion of SSc patients have only limited …